NCT00895596 - Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

December 31, 2007

Conditions

Chronic Hepatitis B

Interventions

DRUG

LB80380

Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg

Trial Locations (4)

Queen Mary Hospital, Hong Kong

Korea University Medical Center, Seoul

Severance Hospital of Yonsei University, Seoul

The Catholic University of Korea, Kangnam St. Mary's Hospital, Seoul